Volume | 43,870 |
|
|||||
News | - | ||||||
Day High | 1.05 | Low High |
|||||
Day Low | 1.01 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Organovo Holdings Inc | ONVO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
1.01 | 1.01 | 1.05 | 1.03 | 1.01 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
342 | 43,870 | US$ 1.04 | US$ 45,543 | - | 0.8911 - 2.33 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:56:44 | 66 | US$ 1.0398 | USD |
Organovo Holdings Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
10.34M | 10.04M | - | 370k | -17.26M | -1.72 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Organovo News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ONVO Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.04 | 1.20 | 0.99 | 1.03 | 238,756 | -0.02 | -1.92% |
1 Month | 1.00 | 1.24 | 0.981 | 1.05 | 144,925 | 0.02 | 2.00% |
3 Months | 1.20 | 1.24 | 0.8911 | 1.06 | 119,327 | -0.18 | -15.00% |
6 Months | 1.31 | 2.05 | 0.8911 | 1.24 | 162,174 | -0.29 | -22.14% |
1 Year | 2.28 | 2.33 | 0.8911 | 1.30 | 96,112 | -1.26 | -55.26% |
3 Years | 9.28 | 11.25 | 0.8911 | 4.13 | 96,334 | -8.26 | -89.01% |
5 Years | 0.9811 | 23.92 | 0.1933 | 1.97 | 417,600 | 0.0389 | 3.96% |
Organovo Description
Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo's key instrument platform is the NovoGen Bioprinter. The firm's 3-D bioprinting technologies create tissues using living cells and biocompatible hydrogels. |